| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today two new contracts to provide integrated chronic condition management solutions for two national employers beginning in the second quarter of 2024.
The first employer, a global private investment group, selected Dario's cardiometabolic suite to help improve outcomes for employees with cardiometabolic health conditions, including diabetes, pre-diabetes, hypertension and weight management needs, including support for individuals taking a GLP-1.
The second employer, a national professional services company, selected Dario's full suite of solutions to deliver personalized support for employees living with cardiometabolic health conditions and commonly co-occurring musculoskeletal and behavioral health needs.
Dario combines intelligent technologies with billions of data insights gathered from a decade of consumer engagement to deliver highly personalized experiences that keep members engaged over time for optimal results. Employees enrolled in Dario's cardiometabolic solution who are taking a GLP-1 medication will also have access to a tailored experience to support long-term behavior change.
"The need for an integrated approach to address the most common and chronic health needs continues to drive demand for Dario's multi-chronic solutions. Our ability to ensure each employee receives proven, highly personalized support – especially with the growing use of GLP-1s – is the reason we believe that more companies like our two new employer clients are selecting Dario and we are excited to deliver the high-value support they require," said Rick Anderson, President of Dario.
Posted In: DRIO
